Pieris Pharmaceuticals (Seite 3)
eröffnet am 06.01.17 13:11:27 von
neuester Beitrag 28.08.23 08:45:50 von
neuester Beitrag 28.08.23 08:45:50 von
Beiträge: 104
ID: 1.244.291
ID: 1.244.291
Aufrufe heute: 0
Gesamt: 11.903
Gesamt: 11.903
Aktive User: 0
ISIN: US7207952026 · WKN: A40A3W · Symbol: PIRS
11,170
USD
+0,09 %
+0,010 USD
Letzter Kurs 02:00:00 Nasdaq
Neuigkeiten
22.08.23 · Sharedeals |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 8,2570 | +96,67 | |
| 17,440 | +44,61 | |
| 1,9750 | +27,42 | |
| 1,8400 | +26,03 | |
| 4,0000 | +25,00 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,7275 | -18,72 | |
| 0,7100 | -19,32 | |
| 0,5350 | -20,15 | |
| 3,0800 | -23,76 | |
| 3,0740 | -77,41 |
Beitrag zu dieser Diskussion schreiben
Feedback
Das war es hier. Bin raus, sehe keinen Mehrwert im Rest der Pipeline.
21.6.
Pieris Pharmaceuticals Announces AstraZeneca Discontinuation of Phase 2a Trial of Elarekibep (PRS-060/AZD1402) Due to New Non-Clinical Safety Findings From 13-week Toxicology Study
https://www.wallstreet-online.de/nachricht/17065536-pieris-p…
...
Pieris Pharmaceuticals Announces AstraZeneca Discontinuation of Phase 2a Trial of Elarekibep (PRS-060/AZD1402) Due to New Non-Clinical Safety Findings From 13-week Toxicology Study
https://www.wallstreet-online.de/nachricht/17065536-pieris-p…
...
https://www.accesswire.com/756232/Pieris-Pharmaceuticals-Ann…
Pieris Pharmaceuticals Announces Presentation of Promising Preclinical Data for PRS-220 at ATS 2023 International Conference
BOSTON, MA / ACCESSWIRE / May 21, 2023 / Pieris Pharmaceuticals, Inc. (Nasdaq:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, announced the presentation of preclinical data from the Company's inhaled connective tissue growth factor (CTGF) antagonist program, PRS-220, for idiopathic pulmonary fibrosis (IPF) at the annual American Thoracic Society (ATS) International Conference being held in Washington, D.C. May 19-24, 2023.
The poster will be presented on May 21, 2023, from 11:30 AM to 1:15 PM (Session A67, P1052) and demonstrates that PRS-220 achieved proof of concept in a silica-induced lung fibrosis mouse model when delivered to the lung by inhalation and outperformed a systemically administered CTGF-targeting monoclonal antibody, reinforcing the transformative potential of a local intervention in this pathway. A copy of the presentation can be viewed HERE.
The poster also includes preclinical data demonstrating a favorable profile of PRS-220 for inhaled delivery and CTGF targeting in the lung, including a superior lung biodistribution profile compared to a systemically administered anti-CTGF monoclonal antibody, a lung PK profile supporting once or twice daily dosing in humans, and desired aerosol performance upon nebulization to effectively target pulmonary tissue of interest.
"Targeting CTGF is a clinically validated treatment approach for IPF, as shown by trial data from the intravenously delivered monoclonal antibody pamrevlumab. Based on the pulmonary pathophysiology associated with IPF, we believe that directly inhibiting CTGF in the lung with an inhaled therapy could result in more efficient target saturation, superior clinical efficacy, and greater convenience for patients," said Shane Olwill Ph.D., Chief Development Officer at Pieris. "Our ongoing PRS-220 Phase 1 healthy volunteer study is on track to provide data in the second half of this year, and we are eager to initiate development in IPF patients to further evaluate the clinical potential of this promising investigational medicine."
About PRS-220:
PRS-220 is an inhaled Anticalin protein targeting CTGF for the treatment of IPF and other fibrotic lung diseases. Previously reported preclinical data for PRS-220 demonstrated superior on-target potency compared to pamrevlumab, an intravenously infused CTGF antagonist in late-stage clinical development. Pieris continues to benefit from a meaningful grant from the Bavarian government, which supports early-stage development of this program.
...
Pieris Pharmaceuticals Announces Presentation of Promising Preclinical Data for PRS-220 at ATS 2023 International Conference
BOSTON, MA / ACCESSWIRE / May 21, 2023 / Pieris Pharmaceuticals, Inc. (Nasdaq:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, announced the presentation of preclinical data from the Company's inhaled connective tissue growth factor (CTGF) antagonist program, PRS-220, for idiopathic pulmonary fibrosis (IPF) at the annual American Thoracic Society (ATS) International Conference being held in Washington, D.C. May 19-24, 2023.
The poster will be presented on May 21, 2023, from 11:30 AM to 1:15 PM (Session A67, P1052) and demonstrates that PRS-220 achieved proof of concept in a silica-induced lung fibrosis mouse model when delivered to the lung by inhalation and outperformed a systemically administered CTGF-targeting monoclonal antibody, reinforcing the transformative potential of a local intervention in this pathway. A copy of the presentation can be viewed HERE.
The poster also includes preclinical data demonstrating a favorable profile of PRS-220 for inhaled delivery and CTGF targeting in the lung, including a superior lung biodistribution profile compared to a systemically administered anti-CTGF monoclonal antibody, a lung PK profile supporting once or twice daily dosing in humans, and desired aerosol performance upon nebulization to effectively target pulmonary tissue of interest.
"Targeting CTGF is a clinically validated treatment approach for IPF, as shown by trial data from the intravenously delivered monoclonal antibody pamrevlumab. Based on the pulmonary pathophysiology associated with IPF, we believe that directly inhibiting CTGF in the lung with an inhaled therapy could result in more efficient target saturation, superior clinical efficacy, and greater convenience for patients," said Shane Olwill Ph.D., Chief Development Officer at Pieris. "Our ongoing PRS-220 Phase 1 healthy volunteer study is on track to provide data in the second half of this year, and we are eager to initiate development in IPF patients to further evaluate the clinical potential of this promising investigational medicine."
About PRS-220:
PRS-220 is an inhaled Anticalin protein targeting CTGF for the treatment of IPF and other fibrotic lung diseases. Previously reported preclinical data for PRS-220 demonstrated superior on-target potency compared to pamrevlumab, an intravenously infused CTGF antagonist in late-stage clinical development. Pieris continues to benefit from a meaningful grant from the Bavarian government, which supports early-stage development of this program.
...
Jetze wo die MC gut runtergekommen ist, wegen dem AZ Zusatzjahr und Kohla ran muss, macht doch Yoder klar, dass er eventuell die IO Anticalin Sparte versilbern will.
Seht ihr da gute Chancen? Wieviel könnten die dadurch erdealen? is ein ipo denkbar?
Seht ihr da gute Chancen? Wieviel könnten die dadurch erdealen? is ein ipo denkbar?
Pieris Pharmaceuticals Announces Presentation of Positive Clinical Data for Cinrebafusp Alpa (PRS-343) At 2023 AACR Annual Meeting
https://www.pieris.com/investors/news-events/press-releases/…
"The ability to drive response in patients who progressed on the most potent currently available therapies provides further evidence of the differentiation of cinrebafusp alfa in the HER2 landscape as well as the overall 4-1BB franchise. Beyond cinrebafusp alfa, we look forward to the progression of-and future data read-outs for-the broader 4-1BB franchise, including our PD-L1/4-1BB bispecific in collaboration with Servier in Phase 1 studies, our CD228/4-1BB bispecific with Seagen in Phase 1 studies, and our GPC-3/4-1BB bispecific with Boston Pharmaceuticals entering the clinic shortly."
https://www.pieris.com/investors/news-events/press-releases/…
"The ability to drive response in patients who progressed on the most potent currently available therapies provides further evidence of the differentiation of cinrebafusp alfa in the HER2 landscape as well as the overall 4-1BB franchise. Beyond cinrebafusp alfa, we look forward to the progression of-and future data read-outs for-the broader 4-1BB franchise, including our PD-L1/4-1BB bispecific in collaboration with Servier in Phase 1 studies, our CD228/4-1BB bispecific with Seagen in Phase 1 studies, and our GPC-3/4-1BB bispecific with Boston Pharmaceuticals entering the clinic shortly."
Trading Spotlight
Verzögerung bei AstraZeneca
https://www.pieris.com/investors/news-events/press-releases/…
KE oder lizensiert Yoder wieder was aus.
https://www.pieris.com/investors/news-events/press-releases/…
KE oder lizensiert Yoder wieder was aus.
Is Pieris Pharmaceuticals Inc (PIRS) a Leader in the Biotechnology Industry?
The 60 rating InvestorsObserver gives to Pieris Pharmaceuticals Inc (PIRS) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 72 percent of stocks in the Biotechnology industry, PIRS’s 60 overall rating means the stock scores better than 60 percent of all stocks.Quelle: https://www.investorsobserver.com/news/stock-update/is-pieri…
10.1.
Pieris Pharmaceuticals Announces $5 Million Milestone from Seagen for Initiation of Phase 1 Trial of CD228 x 4-1BB Bispecific Molecule (Mabcalin SGN-BB228 (PRS-346)
https://www.accesswire.com/734629/Pieris-Pharmaceuticals-Ann…
...
Pieris Pharmaceuticals Announces $5 Million Milestone from Seagen for Initiation of Phase 1 Trial of CD228 x 4-1BB Bispecific Molecule (Mabcalin SGN-BB228 (PRS-346)
https://www.accesswire.com/734629/Pieris-Pharmaceuticals-Ann…
...
Antwort auf Beitrag Nr.: 72.931.909 von biogenetic am 17.12.22 00:14:31Wobei Übernahme kann es eigentlich nicht sein, wenn es bis May 2024 zurückgehalten wird.
Sehr spannend.
Sehr spannend.
Confidential Treatment Order
Informationen werden zurückgehalten die einen Wettbewerbsnachteil hätten. https://www.sec.gov/Archives/edgar/data/1583648/999999999722…
Könnte eine Übernahme sein mit einem bereits geeigneten Preis, damit es nicht zu einem Bieter Wettstreit kommt.
Oder aber es geht um die zwei bisher zurückgehaltenen Projekte von Astra Zeneca.
Durchsuchen
Pieris Pharmaceuticals
